Abstract library

145 results for "64Cu-dotatate".
#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms
Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Esben Andreas Carlsen
#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Mathias Loft
#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jonathan Wadsley
Authors: Wadsley J, Shah T, ...
#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE
Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Prof. Anders Sundin
#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Hong Song
Authors: Song H, Kunz P, Franc B, Moradi F, ...
#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas
#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT
#2797 Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review
Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Dr Persefoni Ioannou
#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Song
Authors: Song H, Kunz P, Fisher G, Franc B, ...
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...